

## Special Issue

# Strategies for the Monitoring, Treatment, and Prevention of Mpox and Other Poxvirus Infections

### Message from the Guest Editors

Poxviruses can infect a remarkably wide range of hosts, making them a one-health concern for veterinary and human medicine worldwide. It is encouraging that some poxviral infections, are already vaccine-preventable or are close to being so. Addressing epidemiologic, clinical, and immunologic aspects in animals and humans is necessary for understanding and improving the management of poxvirus infections, including actionable primary prevention. This Special Issue is dedicated to current and future strategies to enhance the monitoring, treatment, and prevention of poxviral diseases, with a special focus on, but not limited to, mpox. Research may include the following:

- Epidemiology and surveillance of poxvirus infections;
- Risk assessments of zoonotic spillover and the risk of epidemics requiring public health action;
- Studies of the immunogenicity, efficacy, and/or safety of poxvirus vaccines;
- Identification of poxvirus therapeutics and/or novel vaccine candidates;
- Public health and one-health approaches toward enhanced infection control;
- Investigation of vaccination coverage, hesitancy, and/or enhanced vaccine communication.

### Guest Editors

Dr. Patrick Obermeier

Department of Infectious Diseases, Vaccine Safety Initiative, Berlin, Germany

Dr. Susanne Buder

Department of Dermatology and Venereology, Vivantes Hospital Neukölln, Berlin, Germany

### Deadline for manuscript submissions

31 December 2025



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/203032](https://mdpi.com/si/203032)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).